If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
80.90    -3.80 (-4.49%)
Bid:
81.50
Ask:
82.30
Spread: 0.80 (0.982%)
Market Cap: £132.63m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q1 Trading update

26 Apr 2018 07:00

RNS Number : 1543M
Synthomer PLC
26 April 2018
 

April 26th 2018

Synthomer plc

Q1 Trading update

Solid Q1 performance in line with expectations; 2018 outlook unchanged

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the first quarter ended March 31st, 2018.

Trading

Europe and North America

The Europe and North America segment delivered another solid performance. Volumes were higher than the comparative period predominantly reflecting the positive impact of the Speciality Additives and Pischelsdorf SBR latex acquisitions. Unit margins were marginally lower mainly due to the transactional impact of European sales denominated in US dollars.

Asia and Rest of World

The Asia and Rest of World segment remained stable with performance in line with our expectations. Nitrile latex volumes were marginally higher than a weaker comparative period when customer spending was impacted by the volatile raw material environment. Unit margins were broadly in line with Q1 2017. We remain cautiously optimistic on the continued Nitrile latex demand growth and margin development recognising that our 90kt capacity is on track to come on line in late Q3 2018.

Financial Position

Net debt increased from £180m at the year end to £246m at 31 March 2018. This reflected completion of the acquisition of the BASF Austrian SBR business and assets in Pischelsdorf for €29m (£25m) in January and seasonal working capital movements which was, as we saw in 2017, impacted by a rising raw material price environment.

2018 outlook unchanged

Overall, the Group continues to trade in line with the Board's expectations, and accordingly the view for Full Year 2018 remains unchanged.

-ENDS-

 

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Charles Armitstead

Stephen Bennett, Chief Financial Officer

Teneo

Tel: + 44 1279 436211

Tel: + 44 20 3603 5220

 

The Company will hold a conference call for investors and analysts at 0800 BST today. 

Please dial 0800 3589473 PIN: 92017967# to gain access to the call.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKPDKCBKDCQB
Date   Source Headline
7th Dec 20057:01 amRNSAdmission to trading on AIM
6th Dec 20054:23 pmRNSDirector Declaration
6th Dec 20054:18 pmRNSDirectorate Change
2nd Dec 200510:07 amRNSSale of Autoclenz Limited
15th Nov 20054:54 pmRNSHolding(s) in Company
31st Oct 20059:45 amRNSProposed sale - Autoclenz Ltd
5th Oct 20052:36 pmRNSDirector/PDMR Shareholding
29th Sep 200512:08 pmRNSDirector/PDMR Shareholding
14th Sep 20053:02 pmRNSHolding(s) in Company
17th Aug 20059:50 amRNSNotice of Results
13th Jul 20053:46 pmRNSChief Operating Officer
1st Jul 200511:15 amRNSJames Robinson Consolidation
10th Jun 20053:12 pmRNSDirector Shareholding
10th Jun 20053:09 pmRNSDirector Shareholding
3rd Jun 20053:16 pmRNSHolding(s) in Company
3rd Jun 20053:12 pmRNSHolding(s) in Company
3rd Jun 20053:11 pmRNSHolding(s) in Company
2nd Jun 200512:41 pmRNSBlocklisting Interim Review
2nd Jun 200511:21 amRNSHolding(s) in Company
1st Jun 20054:55 pmRNSHolding(s) in Company
26th May 20054:49 pmRNSDoc re. AGM Resolutions
26th May 200512:00 pmRNSAGM Statement
23rd May 200511:41 amRNSHolding(s) in Company
21st Apr 200510:36 amRNSAnnual Report and Accounts
31st Mar 20053:41 pmRNSSale of Brencliffe Limited
23rd Mar 20053:45 pmRNSDirector Shareholding
23rd Mar 20053:44 pmRNSDirector Shareholding
4th Mar 20054:16 pmRNSDirector Shareholding
3rd Mar 20057:00 amRNSFinal Results
15th Feb 20058:51 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.